Budai Irgalmasrendi Korhaz Nonprofit Kft.
- Address
- lock Available on a paid plan
Cardiovascular and Thromboembolic Research
At Budai Irgalmasrendi Korhaz Nonprofit Kft. in Budapest, clinical research in cardiovascular disease focuses on preventing thromboembolic disease after major orthopedic surgery and improving protection against blood clots.
- Preventing venous thromboembolism after knee replacement
- Comparing a new approach with standard clot-prevention treatment
These studies aim to improve patient safety and reduce the risk of serious post-surgical complications.
Autoimmune Disease Studies
The site is also active in immune system diseases, with trials centered on systemic lupus erythematosus and rheumatoid arthritis. The research is designed to assess whether new therapies can better control inflammation and disease activity.
- Evaluating treatment effectiveness in SLE
- Testing new options for ACPA-positive rheumatoid arthritis
- Studying responses in moderate-to-severe rheumatoid arthritis
These trials reflect a strong focus on finding more effective care for people whose symptoms remain difficult to manage with existing medicines.
Musculoskeletal and Systemic Inflammation Research
Clinical trials at this hospital also address musculoskeletal diseases and complex autoimmune conditions, including systemic sclerosis associated with interstitial lung disease. The goal is to better understand how treatments may affect both disease control and overall function.
- Assessing treatment impact in systemic sclerosis
- Monitoring lung-related outcomes in interstitial lung disease
- Exploring therapies for chronic inflammatory disease
Work in this area supports the development of therapies that may help patients manage long-term symptoms and preserve quality of life.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 therapeutic areas and 15 of 20 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AbbVie Deutschland GmbH & Co. KG2trials
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 332 other sites in Hungary
Therapeutic Area Benchmark — Hungary
Select a therapeutic area to compare against other sites in Hungary.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Hungary
Market Share
Country: Hungary
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Budai Irgalmasrendi Korhaz Nonprofit Kft.
lock Showing 1 of 9 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2, Multicenter, Randomized, Open-Label, Active-Control Study of REGN9933, a Factor XI Monoclonal Antibody, for Prevention of Venous Thromboembolism after Elective, Unilateral, Total Knee Arthroplasty | Regeneron Pharmaceuticals Inc. | Phase II | Not Recruiting | Jun 2023 | May 2024 |
IMP list
lock Showing 1 of 20 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Enoxaparin Sodium | 2 | Unknown | 2023-06-26 | 2024-06-27 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.